Jack Whelan of Andover, MA USA is an eight-year survivor of a rare not-yet-curable blood cancer who has chosen forward-looking science, what’s in Clinical Trials to manage this disease. As there is no “standard of care” for this cancer that affects roughly 1500 patients, health care providers take an empirical approach, borrowing chemotherapies from other blood cancers.
Taking a more active role in choosing his treatment options, travel with Jack on an intensely personal and sometimes humorous bumpy ride on the road to Precision Medicine that is still under construction. Participating in seven Clinical Trials, he has achieved repeated Progression Free Survival periods by sidestepping the more popular out-of-date rules in Clinical Research and avoiding the outdated biometry associated with this Research-Centric rather than Patient-Centric care. Jack believes engaging all parties including patients with biomarker data sooner can dramatically improve clinical trials outcomes.
AVAILABILITY: less than 10 hours/week
Speak at a variety of Life Sciences conferences in the U.S. and Europe using his personal lifetime experiences as an IT Research Analyst/VP Sales and more recent experiences as a Research Advocate participating in many clinical trials for a rare blood cancer and metastatic prostate cancer. He's expertise is centered on the Clinical Trials process, how to improve, Companion Diagnostics (CDx), Precision Medicine and employing latest generation IT technology in CTMS and ePRO/COA systems. A decided friend to BioPharma, CRO and other life sciences firms.